到2021年,班曼农场肺气肿病患者的重症Oat - phase比较开始和结束

Evita Nurhayati, Arif Mulyanto, Tantri Analisawati Sudarsono, Linda Wijaya
{"title":"到2021年,班曼农场肺气肿病患者的重症Oat - phase比较开始和结束","authors":"Evita Nurhayati, Arif Mulyanto, Tantri Analisawati Sudarsono, Linda Wijaya","doi":"10.33084/jsm.v9i1.5192","DOIUrl":null,"url":null,"abstract":"Treatment of tuberculosis with main anti-tuberculosis drugs (OAT) includes isoniazid (INH), rifampin (RIF), ethambutanol (EMB), streptomycin (SM), and pyrazinamide (PZA). Although most Anti-Tuberculosis Drugs (OAT) are acceptable in therapy, they have potential side effects, including the side effects of hematological reactions such as anemia. This study's purpose was to compare HB levels before and after the intensive  phase of Anti-Tuberculosis Drugs treatment in TB patients at Petanahan Public Health Care Center, Kebumen Regency. This was an analytic observational study with a cross-sectional design. The sample in this study was 28 people. The result showed that the average Hb level of pulmonary TB patients at Petanahan Public Health Care Center before and after the treatment were 11.05 g/dl and 11.6 g/dl, respectively. Therefore there was an effect of comparing Hb levels before and after the intensive phase of Anti-Tuberculosis Drugs treatment in pulmonary TB patients at the Petanahan Public Health Center in 2021. The increase in the average Hb levels of patients with pulmonary TB before and after the treatment was 0.55. The sig values obtained from the analysis of Hb levels before and after the treatment were a = 0.200 (p0.005) and 0.023, respectively.  Due to the P value (0.023 < 0.05), Ho was rejected. It meant that there was a difference in Hb levels before and after the Intensive Phase of Anti-Tuberculosis Drugs treatment in patients with pulmonary TB at Petanahan Public Health Care Center, Kebumen Regency.","PeriodicalId":161561,"journal":{"name":"Jurnal Surya Medika","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perbandingan Kadar HB Sebelum dan Sesudah Pengobatan Oat Fase Intensif pada Penderita Tuberkulosis Paru di Puskesmas Petanahan Kebumen Tahun 2021\",\"authors\":\"Evita Nurhayati, Arif Mulyanto, Tantri Analisawati Sudarsono, Linda Wijaya\",\"doi\":\"10.33084/jsm.v9i1.5192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment of tuberculosis with main anti-tuberculosis drugs (OAT) includes isoniazid (INH), rifampin (RIF), ethambutanol (EMB), streptomycin (SM), and pyrazinamide (PZA). Although most Anti-Tuberculosis Drugs (OAT) are acceptable in therapy, they have potential side effects, including the side effects of hematological reactions such as anemia. This study's purpose was to compare HB levels before and after the intensive  phase of Anti-Tuberculosis Drugs treatment in TB patients at Petanahan Public Health Care Center, Kebumen Regency. This was an analytic observational study with a cross-sectional design. The sample in this study was 28 people. The result showed that the average Hb level of pulmonary TB patients at Petanahan Public Health Care Center before and after the treatment were 11.05 g/dl and 11.6 g/dl, respectively. Therefore there was an effect of comparing Hb levels before and after the intensive phase of Anti-Tuberculosis Drugs treatment in pulmonary TB patients at the Petanahan Public Health Center in 2021. The increase in the average Hb levels of patients with pulmonary TB before and after the treatment was 0.55. The sig values obtained from the analysis of Hb levels before and after the treatment were a = 0.200 (p0.005) and 0.023, respectively.  Due to the P value (0.023 < 0.05), Ho was rejected. It meant that there was a difference in Hb levels before and after the Intensive Phase of Anti-Tuberculosis Drugs treatment in patients with pulmonary TB at Petanahan Public Health Care Center, Kebumen Regency.\",\"PeriodicalId\":161561,\"journal\":{\"name\":\"Jurnal Surya Medika\",\"volume\":\"20 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jurnal Surya Medika\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33084/jsm.v9i1.5192\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Surya Medika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33084/jsm.v9i1.5192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

治疗结核病的主要抗结核药物包括异烟肼(INH)、利福平(RIF)、乙胺丁醇(EMB)、链霉素(SM)和吡嗪酰胺(PZA)。虽然大多数抗结核药物(OAT)在治疗中是可接受的,但它们有潜在的副作用,包括血液学反应的副作用,如贫血。本研究的目的是比较Kebumen Regency Petanahan公共卫生保健中心结核病患者抗结核药物强化治疗前后的HB水平。这是一项横断面设计的分析性观察研究。这项研究的样本是28人。结果显示,Petanahan公共卫生保健中心肺结核患者治疗前后的平均Hb水平分别为11.05 g/dl和11.6 g/dl。因此,比较2021年Petanahan公共卫生中心肺结核患者抗结核药物强化治疗前后的Hb水平具有效果。治疗前后肺结核患者平均Hb水平升高0.55。治疗前后Hb水平分析的sig值分别为a = 0.200 (p0.005)和0.023。由于P值(0.023 < 0.05),Ho被拒绝。这意味着在Kebumen Regency Petanahan公共卫生保健中心肺结核患者的抗结核药物强化治疗阶段前后Hb水平存在差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Perbandingan Kadar HB Sebelum dan Sesudah Pengobatan Oat Fase Intensif pada Penderita Tuberkulosis Paru di Puskesmas Petanahan Kebumen Tahun 2021
Treatment of tuberculosis with main anti-tuberculosis drugs (OAT) includes isoniazid (INH), rifampin (RIF), ethambutanol (EMB), streptomycin (SM), and pyrazinamide (PZA). Although most Anti-Tuberculosis Drugs (OAT) are acceptable in therapy, they have potential side effects, including the side effects of hematological reactions such as anemia. This study's purpose was to compare HB levels before and after the intensive  phase of Anti-Tuberculosis Drugs treatment in TB patients at Petanahan Public Health Care Center, Kebumen Regency. This was an analytic observational study with a cross-sectional design. The sample in this study was 28 people. The result showed that the average Hb level of pulmonary TB patients at Petanahan Public Health Care Center before and after the treatment were 11.05 g/dl and 11.6 g/dl, respectively. Therefore there was an effect of comparing Hb levels before and after the intensive phase of Anti-Tuberculosis Drugs treatment in pulmonary TB patients at the Petanahan Public Health Center in 2021. The increase in the average Hb levels of patients with pulmonary TB before and after the treatment was 0.55. The sig values obtained from the analysis of Hb levels before and after the treatment were a = 0.200 (p0.005) and 0.023, respectively.  Due to the P value (0.023 < 0.05), Ho was rejected. It meant that there was a difference in Hb levels before and after the Intensive Phase of Anti-Tuberculosis Drugs treatment in patients with pulmonary TB at Petanahan Public Health Care Center, Kebumen Regency.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信